Eu: Meta To Offer Choices On Personal Facebook And Instagram Ads

Investing.com -- Agios Pharmaceuticals (NASDAQ:AGIO) stock fell 7% after the company announced that the U.S. Food and Drug Administration (FDA) has not yet issued a regulatory decision on its supplemental New Drug Application (sNDA) for mitapivat.

The application, which seeks approval for mitapivat in the treatment of adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, remains under active review despite passing its December 7, 2025, Prescription Drug User Fee Act (PDUFA) goal date.

The commercial-stage biopharmaceutical company, which focuses on delivering medicines for patients with rare diseases, stated it is working closely with the FDA to finalize labeling documents and Risk Evaluation and Mitigation Strategy (REMS) materials for the drug.

In its announcement, Agios emphasized that the FDA has not requested any new or additional efficacy or safety data, and the company has not submitted such information. However, the regulatory agency has not provided a timeline for when it will make its final decision.

Agios indicated it continues to work "expeditiously" with the FDA to conclude the review process for the supplemental application. The delay creates uncertainty for investors who had anticipated a decision by the scheduled PDUFA date.

Mitapivat is being evaluated as a potential treatment option for thalassemia, a group of inherited blood disorders characterized by reduced or abnormal production of hemoglobin, which can lead to anemia and other complications.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Kepler Cheuvreux upgraded Swiss industrial and flow solutions specialist Georg Fischer AG (SIX:GF) to “buy” from “hold” rating, on Monday, while cutting its price target to CHF62 from CHF65. 

With shares at CHF53.30 on December 5, the new target implies 16.3% upside. The broker flags valuation support, a constructive medium-term demand outlook, and progress in the company’s ongoing portfolio transformation.

Georg Fischer trades at 11.3x 12-month forward EV/EBITDA, a discount to the 11.8x peer median and 12x MSCI Europe Capital Goods Index. 

Analyst Martin Flueckiger notes the stock’s 22.4% year-to-date decline, retreating from a CHF73.55 March 2025 peak and giving up gains made after the October 2024 announcement of its transition to a pure-play flow solutions business. 

The weakness is attributed to geopolitical tensions and indirect effects of US tariff policy on customer investment decisions, delaying orders, rather than issues in execution.

The company has executed a series of divestments reducing portfolio complexity and strengthening its balance sheet. 

The CHF630 million divestment of GF Machining Solutions to United Grinding in June 2025 generated a CHF140 million book gain, with proceeds used for debt reduction. 

In July 2025, GF agreed to sell the automotive business of Casting Solutions to Nemak for $336 million, excluding the Leipzig foundry and aerospace assets. 

In October 2025, GF signed to sell the Leipzig iron foundry to Linamar for EUR45m, closing by year-end. The GF Precicast divestiture is expected in 1H26.

On the acquisition side, Georg Fischer purchased German valve manufacturer VAG Group for CHF200 million in May 2025 to expand infrastructure coverage. Integration of Uponor continues, with synergy expectations of CHF25 million–30 million in 2025 and CHF40 million–50 million by 2027.

Kepler expects 2025 group sales of CHF4,100m, down 0.8% organically and 14.1% in reported terms, driven by a 9% decline due to scope effects and a 4.3% adverse foreign exchange impact.

Adjusted EBIT is estimated at CHF348 million, an 8.5% margin. The Flow Solutions segment EBIT is forecast at CHF331 million, or 11% margin, within GF’s 10.5%-12.5% guidance range.

For 2026, the firm forecasts 2.9% organic growth, an expected negative 20.7% scope effect from Casting Solutions deconsolidation, and a  negative 2.3% FX, implying CHF3.28 billion reported sales, down 20.1%. 

Adjusted EBIT is projected at CHF376 million, with 300bps margin expansion to 11.5% from operating leverage and synergies. 

In 2027, Kepler models 4.9% organic growth, CHF420 million adjusted EBIT, and 70bps additional margin expansion.

Investing.com -- Kepler Cheuvreux upgraded Swiss industrial and flow solutions specialist Georg Fischer AG (SIX:GF) to “buy” from “hold” rating, on Monday, while cutting its price target to CHF62 from CHF65. 

With shares at CHF52.80 on Monday, the new target implies about 17% upside. The broker points to valuation support, a constructive medium-term demand outlook, and ongoing progress in the portfolio transformation.

Georg Fischer trades at 11.3x 12-month forward EV/EBITDA, a discount to the 11.8x peer median and 12x MSCI Europe Capital Goods Index. 

Analyst Martin Flueckiger notes the stock’s 22.4% year-to-date decline, retreating from a CHF73.55 March 2025 peak and giving up gains made after the October 2024 announcement of its transition to a pure-play flow solutions business. 

The weakness is attributed to geopolitical tensions and indirect effects of US tariff policy on customer investment decisions, delaying orders, rather than issues in execution.

The company has executed a series of divestments reducing portfolio complexity and strengthening its balance sheet. 

The CHF630 million divestment of GF Machining Solutions to United Grinding in June 2025 generated a CHF140 million book gain, with proceeds used for debt reduction. 

In July 2025, GF agreed to sell the automotive business of Casting Solutions to Nemak for $336 million, excluding the Leipzig foundry and aerospace assets. 

In October 2025, GF signed to sell the Leipzig iron foundry to Linamar for EUR45m, closing by year-end. The GF Precicast divestiture is expected in 1H26.

On the acquisition side, Georg Fischer purchased German valve manufacturer VAG Group for CHF200 million in May 2025 to expand infrastructure coverage. Integration of Uponor continues, with synergy expectations of CHF25 million–30 million in 2025 and CHF40 million–50 million by 2027.

Kepler expects 2025 group sales of CHF4.10 billion, down 0.8% organically and 14.1% in reported terms, driven by a 9% decline due to scope effects and a 4.3% adverse foreign exchange impact.

Adjusted EBIT is estimated at CHF348 million, an 8.5% margin. The Flow Solutions segment EBIT is forecast at CHF331 million, or 11% margin, within GF’s 10.5%-12.5% guidance range.

For 2026, the firm forecasts 2.9% organic growth, an expected negative 20.7% scope effect from Casting Solutions deconsolidation, and a  negative 2.3% FX, implying CHF3.28 billion reported sales, down 20.1%. 

Adjusted EBIT is projected at CHF376 million, with 300bps margin expansion to 11.5% from operating leverage and synergies. 

In 2027, Kepler models 4.9% organic growth, CHF420 million adjusted EBIT, and 70bps additional margin expansion.

Investing.com -- CoreWeave (NASDAQ:CRWV) stock fell 4% Monday after the company announced plans to offer $2 billion in convertible senior notes due 2031 in a private offering.

The AI infrastructure company said it intends to grant initial purchasers an option to buy up to an additional $300 million in notes. The notes will be guaranteed by CoreWeave’s wholly owned subsidiaries and will accrue interest payable semi-annually in cash.

CoreWeave plans to use part of the proceeds to fund capped call transactions, which are designed to reduce potential dilution to its Class A common stock upon conversion of the notes. The remainder will be allocated for general corporate purposes.

The notes will mature on December 1, 2031, unless earlier repurchased, redeemed, or converted. Noteholders will have the right to convert their notes under certain circumstances, with CoreWeave settling conversions in cash, shares of its Class A common stock, or a combination of both at its discretion.

The interest rate, initial conversion rate, and other terms will be determined when the offering is priced.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Alphabet’s Gemini app is extending its momentum into November, with fresh third-party data showing accelerating usage trends that outpaced both Google Search and ChatGPT, according to new analysis from Bank of America.

BofA analyst Justin Post said “Gemini +18% m/m, ChatGPT -2%, Google -0.4%” in global web traffic, citing Similarweb data for November. 

Year over year, Gemini’s traffic jumped “+394%” globally, while ChatGPT rose “+54%” and Google ticked up “+0.1%.” In the United States, Gemini traffic rose “+317%” year over year and “+13% m/m,” BofA added.

Mobile engagement has also shown strong momentum, according to the bank. 

Sensor Tower data cited by BofA revealed Gemini’s global mobile daily active users climbed “+352% y/y to 54mn (+14% m/m).” 

Post stated that in November alone, Gemini added “6mn global DAUs,” topping ChatGPT’s “5mn” and Grok’s “1mn.” ChatGPT mobile DAUs were up “264% y/y … (up 2% m/m),” while Google’s mobile usage was flat month over month.

In search, Google’s global share reportedly remained steady. BofA noted that Statcounter showed Google’s worldwide search share “increased 70bps y/y … to 90.0%,” even as U.S. share fell year over year. 

Despite headlines about generative AI competition, the analyst believes the data indicates “Google traffic remains stable & AI-driven usage is largely incremental to the broader Search opportunity.”

Crucially, BofA highlighted that Gemini’s rising traction appears tied to the rollout of the “Gemini 3.0” model, saying early signs show the launch press is “driving consumer traffic,” helping ease investor worries about search disruption.

BofA reiterated its Buy rating on Alphabet, pointing to upcoming catalysts including “new Google agentic capabilities,” a “Gemini app visual focused revamp,” and expanded mobile distribution deals.

Andersen Group (ANDG) has filed for 11,000,000 share IPO at $14-$16 per share.

Morgan Stanley and UBS are serving as lead underwriters.